These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15124270)

  • 1. Serious gastrointestinal events from low dose analgesic use.
    Peura DA
    J Rheumatol; 2004 May; 31(5):1009-10; author reply 1010-1. PubMed ID: 15124270
    [No Abstract]   [Full Text] [Related]  

  • 2. Serious gastrointestinal events from low dose analgesic use.
    Tarone RE; Lipworth L; McLaughlin JK
    J Rheumatol; 2004 May; 31(5):1008-9; author reply 1010-1. PubMed ID: 15124269
    [No Abstract]   [Full Text] [Related]  

  • 3. Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.
    Fries JF; Bruce B
    J Rheumatol; 2003 Oct; 30(10):2226-33. PubMed ID: 14528521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NSAID toxicity: where are we and how do we go forward?
    Hawkey CJ
    J Rheumatol; 2002 Apr; 29(4):650-2. PubMed ID: 11950001
    [No Abstract]   [Full Text] [Related]  

  • 5. NSAIDs questionable as first-line therapy for rheumatic conditions in the elderly.
    Salach RH; Calabrese LH
    J Am Osteopath Assoc; 1994 Sep; 94(9):714, 766. PubMed ID: 7995734
    [No Abstract]   [Full Text] [Related]  

  • 6. Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated.
    Metcalfe S; Dougherty S; McNee W
    BMJ; 2003 Feb; 326(7384):334; author reply 334. PubMed ID: 12575714
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-inflammatory efficacy versus gastrointestinal safety: a dilemma resolved? Introduction.
    Bach GL
    Scand J Rheumatol Suppl; 1992; 96():5-6. PubMed ID: 1439625
    [No Abstract]   [Full Text] [Related]  

  • 8. [NSAID therapy. Gastrointestinal risks of classic NSAID are underestimated].
    MMW Fortschr Med; 2010 May; 152(20):46-7. PubMed ID: 20552882
    [No Abstract]   [Full Text] [Related]  

  • 9. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients.
    Wolfe F; Hawley DJ
    J Rheumatol; 2000 Jul; 27(7):1668-73. PubMed ID: 10914849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
    Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
    Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are rheumatoid arthritis patients more willing to accept non-steroidal anti-inflammatory drug treatment risks than osteoarthritis patients?
    Bagge E; Traub M; Crotty M; Conaghan PG; Oh E; Brooks PM
    Br J Rheumatol; 1997 Apr; 36(4):470-2. PubMed ID: 9159542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A new non-steroidal anti-inflammatory drug pirprofen (rengasil) in the treatment of rheumatoid arthritis and osteoarthrosis].
    Sigidin IaA; Pokryshkin VI
    Ter Arkh; 1987; 59(4):73-6. PubMed ID: 2954253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-steroidal anti-inflammatory drugs (NSAIDs).
    Day RO; Graham GG
    BMJ; 2013 Jun; 346():f3195. PubMed ID: 23757736
    [No Abstract]   [Full Text] [Related]  

  • 15. Meloxicam--a safer NSAID?
    Drug Ther Bull; 1998 Aug; 36(8):62-4. PubMed ID: 9876404
    [No Abstract]   [Full Text] [Related]  

  • 16. [Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program)].
    Alekseeva LI
    Ter Arkh; 2010; 82(8):57-62. PubMed ID: 20873248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions.
    Geis GS; Stead H; Wallemark CB; Nicholson PA
    J Rheumatol Suppl; 1991 Mar; 28():11-4. PubMed ID: 1903808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing the adverse effects of nonsteroidal anti-inflammatory drugs.
    Patrignani P; Tacconelli S; Bruno A; Sostres C; Lanas A
    Expert Rev Clin Pharmacol; 2011 Sep; 4(5):605-21. PubMed ID: 22114888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of selected newer nonsteroidal anti-inflammatory drugs.
    Cummings DM; Amadio P
    Am Fam Physician; 1994 Apr; 49(5):1197-202. PubMed ID: 8154406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversies in COX-2 selective inhibition.
    Simon LS; Smolen JS; Abramson SB; Appel G; Bombardier C; Brater DC; Breedveld FC; Brune K; Burmester GR; Crofford LJ; Dougados M; DuBois RN; Fitzgerald GA; Frishman W; García Rodríguez LA; Hochberg MC; Kalden JR; Laine L; Langman MJ; Prescott SM; van de Putte LB; Whelton A; White WB; Willaims GH
    J Rheumatol; 2002 Jul; 29(7):1501-10. PubMed ID: 12136912
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.